Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Ligand Pharmaceuticals
Deal Size : $516.0 million
Deal Type : Acquisition
Details : Acquisition of Pfenex is expected to contribute a range of strategic benefits to Ligand like access to a proprietary, protein expression technology, utilized in various commercial and development-stage biopharmaceutical programs. Versatile operating busi...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $438.0 million
October 08, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Ligand Pharmaceuticals
Deal Size : $516.0 million
Deal Type : Acquisition
Lead Product(s) : CRM197
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Serum Institute of India Private Limited
Deal Size : Undisclosed
Deal Type : Agreement
Details : Pfenex is eligible to receive annual fees, milestone payments, and royalty based on net sales for all products developed by Serum Institute that use the CRM197 produced via Pfenex Expression Technology.
Product Name : CRM197
Product Type : Vaccine
Upfront Cash : Undisclosed
August 01, 2020
Lead Product(s) : CRM197
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Serum Institute of India Private Limited
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfenex Announces Positive European CHMP Opinion for PF708
Details : Pfenex received a positive opinion for PF708 (branded in Europe as Livogiva™) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Product Name : Livogiva
Product Type : Peptide
Upfront Cash : Inapplicable
June 26, 2020
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Ligand Pharmaceuticals
Deal Size : $516.0 million
Deal Type : Acquisition
Ligand Completes Acquisition of Pfenex Inc
Details : Ligand gains a proprietary platform which uses P. fluorescens bacterium, which are especially well-suited for complex, large-scale protein production that cannot be made by more traditional host systems.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $438.0 million
January 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Ligand Pharmaceuticals
Deal Size : $516.0 million
Deal Type : Acquisition